MARKET

LIFE

LIFE

aTyr Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.240
+0.160
+5.19%
After Hours: 3.160 -0.08 -2.47% 17:34 03/27 EDT
OPEN
2.920
PREV CLOSE
3.080
HIGH
3.280
LOW
2.710
VOLUME
175.46K
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
2.130
MARKET CAP
26.33M
P/E (TTM)
-0.3712
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LIFE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LIFE stock price target is 10.33 with a high estimate of 15.00 and a low estimate of 8.00.

EPS

LIFE News

More
  • aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 2d ago
  • aTyr Pharma EPS misses by $0.06, misses on revenue
  • seekingalpha · 2d ago
  • Atyr Pharma (LIFE) Reports Q4 Loss, Lags Revenue Estimates
  • Zacks · 2d ago
  • aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
  • GlobeNewswire · 2d ago

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About LIFE

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
More

Webull offers kinds of aTyr Pharma Inc stock information, including NASDAQ:LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions.